NAD+ IV Drip Protocols

Based on the available literature, there is extremely limited evidence regarding standardized protocols for intravenous NAD+ administration. The evidence base is insufficient to establish clear dosing or administration guidelines.

Current Evidence Limitations

Only one relevant study was identified that directly addresses intravenous NAD+ administration: a retrospective tolerability pilot study comparing IV NAD+ to nicotinamide riboside. However, specific dosing protocols, infusion rates, or administration guidelines from this study are not detailed in the available evidence.

The remaining literature focuses on:

General NAD+ supplementation (without IV-specific protocols)
Related compounds like nicotinamide mononucleotide
Unrelated clinical studies involving different interventions

Clinical Trial Activity

Several ongoing or planned clinical trials are investigating NAD+ precursors and related compounds, including:

Phase 1 studies of "Coenzyme I for injection" (which may refer to NAD+ compounds)
Studies examining effects on hematopoietic recovery and vascular aging

However, detailed protocol information is not available from these trial registrations.

Protocol Gaps

The literature does not provide adequate evidence for:

Recommended dosing ranges
Infusion rates or duration
Frequency of administration
Patient selection criteria
Monitoring parameters
Safety protocols

Medical Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. NAD+ IV therapy protocols should only be determined and administered by qualified healthcare professionals. Patients should consult with their healthcare provider before considering any NAD+ supplementation or IV therapy.

NAD+ IV Drip

Member access required